pf-04895162
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01691274)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- KCNQ (Kv7) potassium channelACTIVATOR
KCNQ (Kv7) potassium channel activator
- Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) ↗
- Potassium voltage-gated channel subfamily KQT member 2 (KCNQ2) ↗
- Potassium voltage-gated channel subfamily KQT member 3 (KCNQ3) ↗
- Potassium voltage-gated channel subfamily KQT member 5 (KCNQ5) ↗
- Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) ↗
- Voltage-gated potassium channel subunit Kv7.2
- Voltage-gated potassium channel subunit Kv7.4
- Voltage-gated potassium channel subunit Kv7.5
- Voltage-gated potassium channel subunit Kv7.1
- Voltage-gated potassium channel subunit Kv7.3
- Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3)
- Voltage-gated potassium channel KCNQ3/KCNQ4
- Voltage-gated potassium channel KCNQ3/KCNQ5
- KCNQ4/KCNQ5
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- pf-04895162
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01691274 | Phase 1 | Oct 1, 2012 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2012 |
1 organizations
Page 1 / 1